In addition to engineering a potential sale of Optimer Pharmaceuticals, new Chairman and CEO Henry McKinnell shed more light on the alleged misdeeds involving stock grants at the highest levels of the company, Xconomy 's Bruce Bigelow reported.
Optimer Pharmaceuticals CEO Pedro Lichtinger has been shown the door, another casualty resulting from an unusual stock deal that took down the company chairman last year. And former Pfizer CEO Henry McKinnell has stepped in as interim chief while the company considers its strategic alternatives--including a possible sale.
Hank McKinnell has a new biopharma mess to sort out.
Optimer is pocketing a $20 million up-front payment on a new commercial pact for its treatment for C. difficile.